LU67546A1 - - Google Patents

Info

Publication number
LU67546A1
LU67546A1 LU67546A LU67546DA LU67546A1 LU 67546 A1 LU67546 A1 LU 67546A1 LU 67546 A LU67546 A LU 67546A LU 67546D A LU67546D A LU 67546DA LU 67546 A1 LU67546 A1 LU 67546A1
Authority
LU
Luxembourg
Application number
LU67546A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU67546A1 publication Critical patent/LU67546A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
LU67546A 1972-05-05 1973-05-04 LU67546A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2114272A GB1430942A (en) 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes

Publications (1)

Publication Number Publication Date
LU67546A1 true LU67546A1 (de) 1973-07-13

Family

ID=10157915

Family Applications (1)

Application Number Title Priority Date Filing Date
LU67546A LU67546A1 (de) 1972-05-05 1973-05-04

Country Status (16)

Country Link
JP (1) JPS4961150A (de)
AT (1) AT355232B (de)
AU (1) AU475168B2 (de)
BE (1) BE799102A (de)
CA (1) CA1013341A (de)
CH (1) CH617710A5 (de)
DE (1) DE2322532A1 (de)
ES (1) ES414411A1 (de)
FR (1) FR2183792B1 (de)
GB (1) GB1430942A (de)
IE (1) IE37596B1 (de)
IL (1) IL42196A (de)
LU (1) LU67546A1 (de)
NL (1) NL7306234A (de)
SE (1) SE400771B (de)
ZA (1) ZA733035B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
NZ282939A (en) * 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
JP4915427B2 (ja) * 2009-03-30 2012-04-11 ブラザー工業株式会社 液体供給ジョイント、これを使用した液体吐出ヘッド及び記録装置
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
WO2013112605A2 (en) 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
HRP20200995T1 (hr) 2013-04-17 2020-11-27 Sage Therapeutics, Inc. 19-nor neuroaktivni steroidi za metode liječenja
HRP20190232T1 (hr) 2013-04-17 2019-03-22 Sage Therapeutics, Inc. 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
SMT202100229T1 (it) 2013-07-19 2021-05-07 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
SMT202100048T1 (it) 2013-08-23 2021-03-15 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
AU2015331749A1 (en) 2014-10-16 2017-05-04 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
JP6742308B2 (ja) 2014-10-16 2020-08-19 セージ セラピューティクス, インコーポレイテッド Cns障害を処置するための組成物および方法
ES2793237T3 (es) 2014-11-27 2020-11-13 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG11201807785VA (en) 2016-03-08 2018-10-30 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
CN109689673B (zh) 2016-07-11 2023-03-14 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1346292A (fr) * 1962-09-14 1963-12-20 Roussel Uclaf Nouveau procédé de préparation des 21-amino stéroïdes
US3144446A (en) * 1963-12-20 1964-08-11 Upjohn Co Mono and bis nu-(3alpha, 17alpha-dihydroxy-11, 20-dioxo-5beta-pregnan-21-yl) quaternary ammonium salts of triethylenediamine

Also Published As

Publication number Publication date
JPS4961150A (de) 1974-06-13
IE37596B1 (en) 1977-08-31
DE2322532A1 (de) 1973-11-22
CA1013341A (en) 1977-07-05
CH617710A5 (en) 1980-06-13
FR2183792A1 (de) 1973-12-21
IL42196A (en) 1978-10-31
IE37596L (en) 1973-11-05
GB1430942A (en) 1976-04-07
AU475168B2 (en) 1976-08-12
ES414411A1 (es) 1976-02-01
NL7306234A (de) 1973-11-07
ATA395173A (de) 1979-07-15
ZA733035B (en) 1974-04-24
FR2183792B1 (de) 1977-07-15
AT355232B (de) 1980-02-25
BE799102A (fr) 1973-11-05
AU5528473A (en) 1974-11-07
IL42196A0 (en) 1973-07-30
SE400771B (sv) 1978-04-10

Similar Documents

Publication Publication Date Title
JPS4961150A (de)
JPS4967544A (de)
CS165507B1 (de)
CS166318B1 (de)
CS164463B1 (de)
CS161344B1 (de)
CS161342B1 (de)
CS161336B1 (de)
CS157424B1 (de)
CS156360B1 (de)
CS155576B1 (de)
CS155486B1 (de)
CS155482B1 (de)
CS155641B1 (de)
CH574943A5 (de)
CH590252A5 (de)
CH569691A5 (de)
CH570641A5 (de)
CH568886A5 (de)
CH571767A5 (de)
CH572280A5 (de)
CH572429A5 (de)
CH573595A5 (de)
CH574006B5 (de)
CH568043A5 (de)